Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TKI258 in advanced endometrial cancer
NCT01379534Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2011
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of dovitinib in endometrial cancer (EC), sponsored by Novartis. Started Nov 2011; status: completed.
02
Drugs
dovitinib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT01379534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01379534.